MariMed Sets October 28 Vote on 1-for-50 to 1-for-100 Reverse Split to Enable Uplisting
MRMD sits 20% above its 52-week low of $0.061 on elevated volume (2.6× avg).
Summary
MariMed shareholders vote October 28 on a 1-for-50 to 1-for-100 reverse stock split aimed at meeting exchange listing price requirements, with the board retaining discretion to abandon the split.
Key Events · Corporate Governance and Compliance · MRMD
-
Reverse Split Vote Set for October 28
Special meeting scheduled for October 28, 2026 to approve a reverse stock split between 1-for-50 and 1-for-100, with the exact ratio left to board discretion.
-
Share Count Reduction
403,740,510 shares outstanding as of the September 4 record date would shrink to between 8,074,810 (1-for-50) and 4,037,405 (1-for-100) shares.
-
Uplisting Goal
The split is intended to raise the share price above the minimum bid requirement for NYSE American or Nasdaq listing, though the filing warns federal cannabis laws may block any national exchange listing.
-
Board Discretion to Abandon
The board may abandon the reverse stock split even after shareholder approval if it determines the split is no longer in the company's best interests.
Analysis · MRMD · Life Sciences
MariMed's definitive proxy sets a special meeting for October 28, 2026 to vote on a reverse stock split ranging from 1-for-50 to 1-for-100. The board wants the split to lift the share price above the minimum bid requirement for NYSE American or Nasdaq listing. With 403.7 million shares outstanding and the stock trading at $0.0732, the split would reduce the float to between 8.1 million and 4.0 million shares. The filing candidly warns that federal cannabis prohibition may block any national exchange listing regardless of the split, and that the board can abandon the split even after approval. The record date is September 4, 2026, and the board recommends voting FOR both the split and the adjournment proposal.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRMD was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $0.06 to $0.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.